New Weight-Loss injection HDM1005 tested in small early trial
NCT ID NCT06637020
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tested a new drug called HDM1005 in 40 overweight or obese adults. Participants received either the drug or a placebo as a shot under the skin. The main goal was to check safety and how the body processes the drug, not yet to prove it works for weight loss.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
HDM1005 injection
What this could lead to
If this drug proves safe and effective in larger trials, it could become a new option for weight management in people with overweight or obesity.
What could go wrong
This is a very early phase 1 study with only 40 participants, so results may not apply to everyone. The drug may cause side effects or fail to show meaningful weight loss in later studies.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVERWEIGHT AND OBESITY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The Second Affiliated Hospital of Anhui Medical University
Hefei, Anhui, 230000, China